We introduce the boryloxide ligand {(HCNDipp)2BO}− (NBODipp, Dipp = 2,6-di-isopropylphenyl) to actinide chemistry. Protonolysis of [U{N(SiMe3)2}3] with 3 equiv of NBODippH produced the uranium(III) tris(boryloxide) complex [U(NBODipp)3] (1). In contrast, treatment of UCl4 with 3 equiv of NBODippK in THF at room temperature or reflux conditions produced only [U(NBODipp)2(Cl)2(THF)2] (2) with 1 equiv of NBODippK remaining unreacted. However, refluxing the mixture of 2 and unreacted NBODippK in toluene instead of THF afforded the target complex [U(NBODipp)3(Cl)(THF)] (3). Two-electron oxidation of 1 with AdN3 (Ad = 1-adamantyl) afforded the uranium(V)–imido complex [U(NBODipp)3(NAd)] (4). The solid-state structure of 1 reveals a uranium–arene bonding motif, and structural, spectroscopic, and DFT calculations all suggest modest uranium–arene δ-back-bonding with approximately equal donation into the arene π4 and π5 δ-symmetry π* molecular orbitals. Complex 4 exhibits a short uranium(V)–imido distance, and computational modeling enabled its electronic structure to be compared to related uranium–imido and uranium–oxo complexes, revealing a substantial 5f-orbital crystal field splitting and extensive mixing of 5f |ml,ms⟩ states and mj projections. Complexes 1–4 have been variously characterized by single-crystal X-ray diffraction, 1H NMR, IR, UV/vis/NIR, and EPR spectroscopies, SQUID magnetometry, elemental analysis, and CONDON, F-shell, DFT, NLMO, and QTAIM crystal field and quantum chemical calculations.
No takes yet. Share an insight, caveat, or question.
Dan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: